Loading organizations...

§ Private Profile · San Francisco, CA, USA
Neuron23 is a technology company.
Neuron23 is a clinical-stage biotechnology company developing precision medicines for genetically defined neurological and immunological diseases. Primarily focusing on Parkinson's disease, the company integrates data science, human genetics, machine learning-based patient selection, and functional genomics. This sophisticated approach identifies and addresses underlying causes of neurodegenerative conditions.
Neuroscientist Dr. Nancy Stagliano and Adam Knight founded Neuron23 in late 2018. Their insight recognized the heterogeneous nature of neurodegenerative diseases, necessitating personalized medicine. They aimed to revolutionize drug discovery in neurology by applying data science and advanced technologies, inspired by successful precision medicine strategies from oncology.
Neuron23 develops treatments for patients with neurological conditions, especially Parkinson's disease. The company envisions a future where precision medicine systematically identifies patient subgroups, matching disease drivers to targeted therapies. Its mission is to improve lives by creating a new paradigm for managing neurodegenerative diseases.
Neuron23 has raised $311.0M across 4 funding rounds.
Neuron23 has raised $311.0M in total across 4 funding rounds.
Neuron23 has raised $311.0M in total across 4 funding rounds.
Neuron23's investors include Northpond Ventures, Westlake Village BioPartners, Acorn Bioventures, HBM Healthcare Investments, Kleiner Perkins, Redmile Group, SoftBank, Vali Barsan, Cowen Healthcare Investments, HBM Partners, Perceptive Advisors, Surveyor Capital.
Neuron23 has raised $311.0M across 4 funding rounds. Most recently, it raised $97.0M Series D in June 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2025 | $97M Series D | — | Northpond Ventures, Westlake Village BioPartners, Acorn Bioventures, HBM Healthcare Investments, Kleiner Perkins, Redmile Group, Softbank | Announced |
| Mar 1, 2022 | $100M Series C | Vali Barsan | Northpond Ventures, Westlake Village BioPartners, Acorn Bioventures, Cowen Healthcare Investments, HBM Partners, Kleiner Perkins, Perceptive Advisors, Redmile Group, Surveyor Capital | Announced |
| Dec 1, 2020 | $34M Series A | Amrit Nagpal | Northpond Ventures, Westlake Village BioPartners, Acorn Bioventures, Kevin Raidy, HBM Partners, Kleiner Perkins, Perceptive Advisors, Surveyor Capital | Announced |
| Dec 1, 2020 | $80M Series B | — | Northpond Ventures, Westlake Village BioPartners | Announced |
Neuron23 is a clinical-stage biotechnology company developing precision medicines for genetically defined neurological and immunological diseases, primarily targeting Parkinson's disease through LRRK2 inhibitors like NEU-411.[1][2][3][4] It serves patients with neurodegenerative conditions such as early-stage Parkinson's (affecting up to 30% of the ~9 million global cases driven by LRRK2 mutations) and autoimmune disorders like multiple sclerosis and psoriasis via TYK2 inhibitors, solving unmet needs in disease progression by matching therapies to genetically stratified patients using AI-driven biomarkers and companion diagnostics.[1][3][4] The company raised $96.5 million in Series D financing in June 2025 to advance its global Phase 2 NEULARK trial, with first patient dosed and topline data expected in 2027, signaling strong growth momentum backed by investors like Westlake Village BioPartners and SoftBank Vision Fund 2.[1][4]
Neuron23 was founded in late 2018 by leaders in human genetics and machine learning to revolutionize drug discovery for neurodegenerative and immunological diseases using data science and precision approaches inspired by oncology.[2][3] CEO Nancy Stagliano, Ph.D., has driven the vision of subsetting patients by genetic defects—starting with LRRK2 in Parkinson's—to deliver targeted therapies, building a team of drug hunters, geneticists, chemists, biologists, and entrepreneurs.[1][2] Early traction came from leveraging public/private datasets for patient stratification algorithms and partnering with Qiagen on the first companion diagnostic for Parkinson's, setting the stage for clinical advancement amid advances in machine learning and functional genomics.[2][3]
Neuron23 rides the wave of human genetics and AI in precision neurology, mirroring oncology's success in patient matching to improve trial outcomes amid large-scale genomic datasets.[2][3] Timing aligns with rising Parkinson's prevalence (~9 million cases) and tools like machine learning for functional genomics, enabling stratification that traditional one-size-fits-all approaches lack.[1][3] Favorable market forces include biotech investor enthusiasm (e.g., $96.5M Series D) and regulatory push for biomarkers, positioning Neuron23 to influence neuroimmunology by proving genetically targeted therapies reduce failure rates and expand addressable populations.[1][2][3][4]
Neuron23's Phase 2 NEULARK topline in 2027 could validate LRRK2 inhibition, unlocking approvals and expansion to TYK2 programs for broader autoimmune indications.[1][4] Trends like AI-biomarker integration and genetic big data will accelerate its pipeline, potentially evolving it into a neuro-precision leader akin to oncology pioneers. With momentum from recent financing, expect partnerships, Phase 3 trials, and ecosystem impact by delivering the right therapy to the right patients—one genetically defined subset at a time.[1][2][3]